找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Imaging Tumor Response to Therapy; Massimo Aglietta,Daniele Regge Book 2012 Springer-Verlag Italia Srl 2012 Assessment of Response.Functio

[复制链接]
楼主: PLY
发表于 2025-3-27 00:59:58 | 显示全部楼层
http://image.papertrans.cn/i/image/461693.jpg
发表于 2025-3-27 02:05:54 | 显示全部楼层
Response to Treatment: The Role of Imagingsses for some forms of cancer—resulting in a 1% annual decline in mortality from all cancers in the USA since 1990—each year, about 7 million people worldwide and 600,000 in the USA continue to die from this disease [1].
发表于 2025-3-27 08:12:10 | 显示全部楼层
Surrogate Endpoints of Clinical Benefit and, of course, a high priority for patients and society. Similar to the HIV/AIDS community, there have been numerous efforts to accelerate approvals of new drugs but also to shorten the times required in their development and marketing, with positive as well as negative consequences.
发表于 2025-3-27 11:39:13 | 显示全部楼层
Renal Canceross, pyrexia, neuromyopathy, anemia, polycythemia, amyloidosis, elevated erythrocyte sedimentation rate, and abnormal liver function) are found in approximately 20–30% of patients with RCC and about 20–30% of all RCC patients have metastatic disease.
发表于 2025-3-27 16:00:52 | 显示全部楼层
Hepatocellular Carcinomaiated with liver cirrhosis and chronic infection/chronic hepatitis from viral B and C hepatitis but toxic/metabolic diseases (alcohol abuse, hemochromatosis, and nonalcoholic steatohepatitis associated with obesity and diabetes) seem to be closely linked to a higher risk of developing HCC [3–5].
发表于 2025-3-27 18:27:44 | 显示全部楼层
发表于 2025-3-28 00:04:23 | 显示全部楼层
Book 2012 criteria in solid tumors) have provided means to objectively measure tumor response in clinical trials with imaging. These guidelines have been rapidly adopted in clinical practice to monitor patient treatment and for therapy planning. However, relying only on anatomical information is not always s
发表于 2025-3-28 05:08:04 | 显示全部楼层
发表于 2025-3-28 06:20:23 | 显示全部楼层
Pancreatic Cancerine therapy and as the reference treatment arm for clinical trials in this patient population [2, 3]. However, its anti-tumoral activity is disappointing because the response rate is around 10%, median survival about 6 months, and 1-year OS around 20%.
发表于 2025-3-28 10:32:11 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-23 13:36
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表